Tracey Ryan

Payer response to new entrants to the multiple sclerosis (MS) market is mixed as some believe that there remain meaningful, major unmet needs in the MS category, according to The Zitter Group's Spring 2011 Managed Care Biologics and Injectables Index.

A closer look at payer management in oncology reveals trends for both oncologists and payers in this changing environment as health plans continue to seek methods to curtail costs associated with cancer care.